Literature DB >> 7866359

The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30.

J Schaafsma1, D Osoba.   

Abstract

A cross-validation of the Karnofsky Performance Status (KPS) and quality of life (QOL) as measured by item 30 of the quality of life questionnaire developed by the European Organization for Research and Treatment of Cancer Study Group (EORTC QLQ-C30) was conducted using ordered logit analysis and prospective data from a continuous sample of 139 lung cancer patients. The QOL is found to be a much broader concept than the KPS, since it likely captures not only physical functioning but also functioning in the non-physical dimensions of social, emotional, and possibly cognitive well-being as well as the level of distress in the physical dimensions of pain, breathing and fatigue. These results suggest that the palliative treatment of advanced cancer and the terminally ill should be guided by a broad concept of well-being that goes beyond one based only on physical functioning.

Entities:  

Mesh:

Year:  1994        PMID: 7866359     DOI: 10.1007/bf00435393

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

Review 1.  Quality-of-life assessment in cancer treatment protocols: research issues in protocol development.

Authors:  C C Gotay; E L Korn; M S McCabe; T D Moore; B D Cheson
Journal:  J Natl Cancer Inst       Date:  1992-04-15       Impact factor: 13.506

2.  A modular approach to quality-of-life assessment in cancer clinical trials.

Authors:  N K Aaronson; M Bullinger; S Ahmedzai
Journal:  Recent Results Cancer Res       Date:  1988

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

Authors:  H Schipper; J Clinch; A McMurray; M Levitt
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

Review 5.  Performance status assessment among oncology patients: a review.

Authors:  S T Orr; J Aisner
Journal:  Cancer Treat Rep       Date:  1986-12

6.  Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status.

Authors:  W Sachsenheimer; W Piotrowski; T Bimmler
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

7.  Defining the role of radiosurgery in the management of brain metastases.

Authors:  M P Mehta; J M Rozental; A B Levin; T R Mackie; S S Kubsad; M A Gehring; T J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores.

Authors:  N Mackworth; P Fobair; M D Prados
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

9.  A method for assessing the quality of life of cancer patients: replication of the factor structure.

Authors:  J M Bliss; P J Selby; B Robertson; T J Powles
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  The development of a method for assessing the quality of life of cancer patients.

Authors:  P J Selby; J A Chapman; J Etazadi-Amoli; D Dalley; N F Boyd
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

View more
  21 in total

1.  Lessons from traumatic head injury for assessing functional status after brain tumour.

Authors:  J T Lindsay Wilson
Journal:  J Neurooncol       Date:  2012-02-11       Impact factor: 4.130

2.  Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

Authors:  D Osoba; N K Aaronson; M Muller; K Sneeuw; M A Hsu; W K Yung; M Brada; E Newlands
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

3.  Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy.

Authors:  Christina Baggott; Bruce A Cooper; Neyssa Marina; Katherine K Matthay; Christine Miaskowski
Journal:  Cancer Nurs       Date:  2012 Jan-Feb       Impact factor: 2.592

4.  Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group.

Authors:  D Osoba; N Aaronson; B Zee; M Sprangers; A te Velde
Journal:  Qual Life Res       Date:  1997-03       Impact factor: 4.147

5.  Anaemia-related impairment in quality of life in elderly cancer patients prior to chemotherapy.

Authors:  Ulrich Wedding; Bernd Röhrig; Ludger Pientka; Klaus Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2006-12-01       Impact factor: 4.553

6.  The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-22       Impact factor: 4.553

Review 7.  Incorporating Quality of Life Metrics in Interventional Oncology Practice.

Authors:  David Li; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

8.  Quality of life outcomes in patients presenting for evaluation of CNS tumors.

Authors:  Alexander Chaitoff; Nehaw Sarmey; Nicolas R Thompson; Youran Fan; Manmeet Ahluwalia; Irene L Katzan
Journal:  Neurol Clin Pract       Date:  2019-02

Review 9.  Prognostic indicators of 6-month mortality in elderly people with advanced dementia: a systematic review.

Authors:  Meghan A Brown; Elizabeth L Sampson; Louise Jones; Anna M Barron
Journal:  Palliat Med       Date:  2012-11-22       Impact factor: 4.762

10.  Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients.

Authors:  Ulrich Wedding; Bernd Röhrig; Almuth Klippstein; Christina Brix; Ludger Pientka; Klaus Höffken
Journal:  Support Care Cancer       Date:  2007-02-21       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.